Potocki-Lupski Syndrome
Summary
Clinical characteristics.
Potocki-Lupski syndrome (PTLS) is characterized by cognitive, behavioral, and medical manifestations. Cognitively, most individuals present with developmental delay, later meeting criteria for moderate intellectual disability. Behaviorally, issues with attention, hyperactivity, withdrawal, and anxiety may be seen. Some individuals meet criteria for autism spectrum disorder. Medically, hypotonia, oropharyngeal dysphagia leading to failure to thrive, congenital heart disease, hypoglycemia associated with growth hormone deficiency, and mildly dysmorphic facial features are observed. Medical manifestations typically lead to identification of PTLS in infancy; however, those with only behavioral and cognitive manifestations may be identified in later childhood.
Diagnosis/testing.
The diagnosis of PTLS is established by detection of a heterozygous duplication at chromosome 17p11.2 that encompasses RAI1. A recurrent 3.7-Mb duplication accounts for approximately two thirds of 17p11.2 duplications; approximately one third are non-recurrent duplications that encompass RAI1 and vary in size from 0.41 Mb to 19.7 Mb.
Management.
Treatment of manifestations: A multidisciplinary evaluation involving healthcare providers from multiple specialties varies by the age and presenting issues of each individual. Management of all manifestations of PTLS is per standard care.
Surveillance: Routine monitoring for growth deceleration, short stature, failure to thrive; periodic developmental assessment by a developmental specialist; screen for behavior problems at every visit; consultation with a psychiatrist and/or psychologist if there are behavioral concerns; follow up of congenital heart disease as per cardiac consultant.
Genetic counseling.
PTLS is inherited in an autosomal dominant manner. The majority of affected individuals have a de novo duplication; however, parent-to-child transmission has been reported. If the 17p11.2 duplication identified in the proband is not identified in either parent, the risk for future pregnancies could be slightly greater than that of the general population (though still <1%) because of the possibility of parental somatic and or germline mosaicism for the duplication. If one of the parents has the 17p11.2 duplication, the risk to each sib of inheriting the duplication is 50%. It is not possible to reliably predict the phenotype of individuals who inherit the duplication. Prenatal testing and preimplantation genetic testing using chromosomal microarray (CMA) to detect the 17q11.2 duplication found in the proband are possible.
Diagnosis
Suggestive Findings
Potocki-Lupski syndrome (PTLS) should be suspected in individuals with the following [Potocki et al 2007, Soler-Alfonso et al 2011, Neira-Fresneda & Potocki 2015]:
- Neurodevelopmental findings:
- Mild-to-moderate infantile hypotonia with oropharyngeal dysphagia and failure to thrive
- Developmental delay; intellectual disability (typically moderate)
- Communication disorder with verbal apraxia and abnormalities of intonation and prosody
- Sleep-disordered breathing (most evident on sleep studies)
- Features of autism spectrum disorder; hyperactivity
- Congenital heart disease, typically left ventricular outflow track spectrum and/or rhythm disturbances
- Growth hormone deficiency
- Mildly to nonspecific dysmorphic facial features [Potocki et al 2007, Neira-Fresneda & Potocki 2015] (see Figure 1).
Figure 1.
Establishing the Diagnosis
The diagnosis of PTLS is established by detection of a heterozygous duplication at chromosome 17p11.2 that encompasses RAI1 [Potocki et al 2000]. Most individuals with PTLS are identified by chromosomal microarray performed in the context of evaluation for hypotonia, failure to thrive, developmental delay, intellectual disability, or autism spectrum disorder.
For this GeneReview, the 17p11.2 recurrent duplication, observed in approximately two thirds of individuals with PTLS, is defined by a 3.7-Mb duplication at the proximal region of chromosome 17 spanning an approximate interval of 16,757,111-20,219,651 in the reference genome (NCBI Build hg19 genome.ucsc.edu/cgi-bin/hgGateway). Note: Non-recurrent duplications (which encompass RAI1) account for approximately one third of individuals with PTLS and vary in size from 0.41 Mb to 19.7 Mb (see Molecular Pathogenesis).
ISCN nomenclature for the recurrent duplication is: arr[hg19] 17p11.2(16,757,111-20,219,651)x3. Note: Since this duplication is recurrent and mediated by segmental duplications, the unique genetic sequence that is duplicated is the same in all individuals with the syndrome; however, the reported size of the duplication may: (1) be slightly larger or smaller if adjacent segmental duplications are included in the size; and (2) vary based on the design of the microarray used to detect it (see Molecular Pathogenesis).
Although several genes are within the 3.7-Mb recurrent duplication, only RAI1 has been implicated as the dosage-sensitive cause of the phenotype [Bi 2005, Walz et al 2004, Walz et al 2006]. (See Molecular Genetics for genes of interest in the duplicated region.)
The best genomic testing method is chromosomal microarray (CMA) using oligonucleotide or SNP arrays that can detect the recurrent duplication in a proband. The ability to size the duplication depends on the type of microarray used and the density of probes in the 17p11.2 region. Note: (1) This duplication is the reciprocal recombination product of the Smith-Magenis syndrome (SMS) deletion; therefore, this region has been represented since the inception of array CGH technology. (2) Although interphase fluorescent in situ hybridization using RAI1 or high-resolution G-banded chromosome analysis can detect the recurrent 3.7-Mb duplication, these methods are highly dependent on cell preparation and technical skills, and thus lack sensitivity [Potocki et al 2007].
Table 1.
Duplication 1 | Method | Test Sensitivity | |
---|---|---|---|
Proband | At-Risk Family Members | ||
Heterozygous duplication at 17p11.2 2: arr[hg19] 17p11.2(16,757,111-20,219,651)x3 3 [ClinGen ID: ISCA-37418] | CMA 4 | 100% | 100% |
Targeted duplication analysis 5 | Not applicable 6 | 100% |
- 1.
See Molecular Genetics for details of the duplication and genes of interest in the region.
- 2.
For this GeneReview, the 17p11.2 recurrent duplication, observed in approximately two thirds of individuals with PTLS, is defined a 3.7-Mb duplication at the proximal region of chromosome 17 spanning an approximate interval of 16,757,111-20,219,651 in the reference genome. Non-recurrent duplications, which encompass RAI1, account for approximately one third of individuals with PTLS and vary in size from 0.41 Mb to 19.7 Mb.
- 3.
Standardized ISCN annotation and interpretation for genomic variants from the Clinical Genome Resource Project (formerly the International Standards for Cytogenomic Arrays [ISCA] Consortium). Genomic coordinates represent the minimum duplication size associated with the 17p11.2 recurrent duplication as designated by ClinGen. Duplication coordinates may vary slightly based on array design used by the testing laboratory. Note that the size of the duplication as calculated from these genomic positions may differ from the expected duplication size due to the presence of segmental duplications near breakpoints. The phenotype of significantly larger or smaller duplications within this region may be clinically distinct from Potocki-Lupski syndrome (see Genetically Related Disorders).
- 4.
Chromosomal microarray analysis (CMA) using oligonucleotide arrays or SNP arrays. CMA designs in current clinical use target the 17p11.2 region.
- 5.
Targeted duplication analysis methods can include FISH, quantitative PCR (qPCR), and multiplex ligation-dependent probe amplification (MLPA) as well as other targeted quantitative methods.
- 6.
Targeted duplication analysis is not appropriate for an individual in whom the 17p11.2 recurrent duplication was not detected by CMA designed to target this region.
Clinical Characteristics
Clinical Description
Potocki-Lupski syndrome (PTLS) is characterized by developmental delay, intellectual disability, behavioral disturbances, organ system involvement, and mildly dysmorphic facial features [Potocki et al 2007, Treadwell-Deering et al 2010]. See Figure 1.
PTLS can manifest in infancy with hypotonia, oropharyngeal dysphagia leading to failure to thrive, congenital heart disease, and hypoglycemia associated with growth hormone deficiency. In contrast, individuals who are more mildly affected may manifest cognitive and behavioral abnormalities only, and not be diagnosed until later in childhood [Potocki et al 2007, Treadwell-Deering et al 2010, Neira-Fresneda & Potocki 2015].
Neurodevelopmental
Mild-to-moderate infantile hypotonia with oropharyngeal dysphagia is common and contributes to poor feeding and mild-to-moderate gross motor delays [Potocki et al 2007, Soler-Alfonso et al 2011]. Poor feeding or poor weight gain can be an initial presentation. Infants and children have significantly lower weight for age, weight for length, and BMI for age than the reference population [Soler-Alfonso et al 2011].
Although gross motor delay is observed in the vast majority, most will achieve independent walking by age two years. Rarely, independent ambulation can be delayed until age four years.
Cognitive impairment is one of the most common characteristics of PTLS [Potocki et al 2007]. The vast majority of individuals tested have moderate intellectual disability [Treadwell-Deering et al 2010].
Speech delay is universal. Standardized testing has revealed expressive and receptive language impairment which can include articulation difficulties and disordered intonation and prosody [Treadwell-Deering et al 2010]. Some individuals may exhibit verbal apraxia.
While there are no formal studies of articulation and language abilities in teens and adults with PTLS, verbal abilities appear to improve both with age and speech therapy. Little data regarding findings in adults are available; however, adults with a confirmed molecular genetic diagnosis who have been clinically evaluated have cognitive challenges.
Sleep-disordered breathing. Although sleep disturbances are not often clinically recognized and significant airway obstruction is not found on examination, abnormalities frequently evident on sleep studies include sleep-disordered breathing such as mild central and/or obstructive sleep apnea [Potocki et al 2007, Neira-Fresneda & Potocki 2015]. Children with sleep apnea may present with snoring or hyperactivity. In addition, periodic limb movement disorder is commonly observed.
Behavioral difficulties identified by objective measures and by parental reports include attention problems, withdrawal, and high levels of hyperactivity and anxiety. Reported deficits in executive functioning include initiating and shifting activities and working memory.
Autism spectrum disorder (ASD) and/or autistic features (decreased eye contact, motor mannerisms or posturing, sensory hypersensitivity or preoccupation, repetitive behaviors, difficulty with transitions, lack of appropriate functional or symbolic play, and lack of joint attention) are seen in affected individuals [Potocki et al 2007, Treadwell-Deering et al 2010, Neira-Fresneda & Potocki 2015]. Using validated scoring systems (ADI-R and ADOS-G), Treadwell-Deering et al [2010] found that approximately 60% of a small cohort of children with PTLS met criteria for ASD.
Congenital Heart Disease
Cardiovascular anomalies are reported in about 40% of individuals with PTLS [Potocki et al 2007, Jefferies et al 2012]. The anomalies can include atrial septal defect and ventricular septal defect, as well as anomalies within the left ventricular outflow track spectrum including bicuspid aortic valve, dilated aortic root, and hypoplastic left heart [Sanchez-Valle et al 2011, Yusupov et al 2011, Bravo et al 2013].
A smaller percentage of individuals with PTLS have rhythm disturbances detected on ECG [Jefferies et al 2012].
Growth Hormone Deficiency
Five of seven individuals in the original description of PTLS had short stature; one of the five had documented growth hormone deficiency [Potocki et al 2000]. In a second study, one of ten individuals had short stature (but not growth hormone deficiency) [Potocki et al 2007]. Subsequently, additional individuals with PTLS and growth hormone deficiency have been identified, including some with hypoglycemia in infancy and short stature in early childhood [Author, personal observation].
Other
Musculoskeletal features of PTLS that can mimic those seen in connective tissue disorders include severe bilateral clubfeet [Dhanaraj et al 2015], joint hypermobility, kyphoscoliosis, pes planus, and long fingers and toes [Martin et al 2008].
Renal anomalies include hypoplastic, multicystic dysplastic kidneys, and hydronephrosis [Goh et al 2012].
EEG abnormalities observed during sleep include slow occipital dominant rhythm and generalized and/or focal epileptiform abnormalities. Clinical or electroencephalographic seizures have not been reported [Potocki et al 2007, Neira-Fresneda & Potocki 2015].
Other findings include the following [Potocki et al 2007, Neira-Fresneda & Potocki 2015]:
- Hyperopia (common, but not significant enough to require corrective lenses in childhood)
- Mild high-frequency sensorineural hearing loss
- Dental malocclusion and dental crowding
Penetrance
Penetrance is 100%; expression of phenotypic features is variable.
Prevalence
The prevalence of PTLS is approximately one in 25,000 [Greenberg et al 1991, Liu et al 2011].
Differential Diagnosis
The differential diagnosis of Potocki-Lupski syndrome (PTLS) is broad due to the wide spectrum of findings and presence of developmental delay, learning problems, and neuropsychiatric disorders – for which the differential diagnosis is extensive. All manifestations of PTLS can also be seen individually or in combination in individuals with other genomic disorders.
Management
Evaluations and Referrals Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with Potocki-Lupski syndrome (PTLS), the evaluations and referrals summarized in Table 2 (if not performed as part of the evaluation that led to diagnosis) are recommended.
Note: Some evaluations are age dependent and may not be relevant at the time of initial diagnosis (e.g., recommendation for cognitive testing for intellectual disability during infancy).
Table 2.
System/Concern | Evaluation | Comment |
---|---|---|
Growth | Growth assessment for evidence of failure to thrive / short stature |
|
Eyes | Ophthalmologic evaluation for strabismus & refractive errors | |
ENT / Dental | Audiology evaluation & assessment for sleep apnea | Sleep study if sleep apnea is suspected |
Evaluation for dental crowding &/or malocclusion | ||
Cardiovascular | ECG & echocardiogram, incl aortic root measurements | |
Gastroenterology / Nutrition | If failure to thrive is present | |
Genitourinary | Renal ultrasound to evaluate for structural anomalies | |
Musculoskeletal | Clinical evaluation for hypermobility, scoliosis, clubbed feet, & pes planus | Radiographic scoliosis survey (x-rays of spine) based on clinical suspicion |
Endocrine | Assessment for history of hypoglycemia &/or concern for growth hormone deficiency | |
Developmental / Psychiatric | Clinical screening for developmental delay, atypical behavior, inattention, hyperactivity & ASD | Autism Diagnostic Observation Schedule™ (ADOS™) to aid in diagnosis of ASD |
Medical genetics | Consultation w/clinical geneticist &/or genetic counselor |
ASD = autism spectrum disorder; DD = developmental delay
Treatment of Manifestations
Depending on the age and presenting problems of the individual with PTLS, a multidisciplinary evaluation involving healthcare providers from the following specialties is often necessary: audiology, cardiology, dental, developmental pediatrics, endocrinology, feeding, gastroenterology, general pediatrics, clinical genetics, ophthalmology, orthopedics, otolaryngology, physical medicine and rehabilitation, psychiatry, sleep medicine, speech pathology, and urology.
Table 3.
Manifestation/Concern | Treatment | Considerations/Other |
---|---|---|
Strabismus &/or refractive errors | Standard treatment as recommended by ophthalmologist | |
Dental crowding / malocclusion | Standard treatment as recommended by dentist/orthodontist | |
Evidence of sleep apnea | Standard treatment as indicated | Assess for iron deficiency if excessive periodic limb movements are identified on sleep study. |
Poor weight gain / failure to thrive | Feeding tube in the short term if required for nutrition & growth | Diet diary & calorie counts may be requested. |
Hypoglycemia, short stature, evidence of growth hormone deficiency | Standard treatment(s) as recommended by endocrinologist | |
Cardiac anomaly, dilated aortic root/aortopathy, &/or ECG abnormality | Standard treatment as recommended by cardiologist | |
Renal anomaly &/or vesicoureteral reflux | Standard treatment as recommended by nephrologist/urologist |
Developmental Delay / Intellectual Disability Management Issues
The following information represents typical management recommendations for individuals with developmental delay/intellectual disability in the United States; standard recommendations may vary from country to country.
Ages 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the US, early intervention is a nationwide federally funded program available in all states.
Ages 3-5 years. In the US, developmental preschool through the local public school district is recommended. A "full individual evaluation" (FIE) will occur before placement to determine needed services and therapies and will be subsequently integrated into an individualized education plan (IEP).
Ages 5-21 years
- In the US, an IEP based on the individual’s level of function should be developed by the local public school district. Affected children are permitted to remain in the public school district generally until age 21.
- Discussion about transition plans including medical and financial guardianship, financial, vocation/employment, and medical arrangements should begin at age 12 years. Developmental pediatricians can provide assistance with transition to adulthood.
All ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life.
Consideration of private supportive therapies based on the affected individual's needs is recommended. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.
In the US:
- Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
- Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.
Motor Dysfunction
Gross motor dysfunction
- Physical therapy is recommended to maximize strength and mobility and to reduce the risk for later-onset orthopedic complications (e.g., scoliosis). Aquatic therapy and hippotherapy (therapeutic horseback riding) may also be considered.
- Consider use of durable medical equipment as needed (e.g., orthotics, adaptive strollers).Physical medicine and rehabilitation evaluations may be warranted [Neira-Fresneda & Potocki 2015].
Fine motor dysfunction. Occupational therapy is recommended to address difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and handwriting.
Oral motor dysfunction. Feeding therapy, typically from an occupational or speech therapist, is recommended for affected individuals who have difficulty feeding due to poor oral motor control and/or sensory aversions, assuming the individual is safe to eat by mouth.
Communication issues. Consider:
- Speech and language therapy to address receptive and expressive language deficits, articulation abnormalities, and verbal apraxia;
- Evaluation for alternative means of communication (e.g., Augmentative and Alternative Communication) for individuals who have expressive language difficulties.
Social/Behavioral Concerns
Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child’s behavioral, social, and adaptive strengths and weaknesses and is typically performed one on one with a board-certified behavior analyst.
Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications when necessary.
Surveillance
Table 4.
System/Concern | Evaluation | Frequency | Comments |
---|---|---|---|
Growth | Monitoring for growth deceleration, short stature, failure to thrive | At every visit |
|
Eyes | Ophthalmology evaluation | Yearly | |
ENT / Mouth | Audiology evaluation | Newborn hearing screen, then as indicated for speech delay | |
Dental evaluation | Every 6 months starting in early childhood | ||
Cardiovascular | Echocardiogram w/attention to aortic root dimension & ECG | Every 3 yrs, if initial evaluations were normal; otherwise, as directed by cardiologist | |
Musculoskeletal | Monitoring for development of scoliosis | Clinical examination at every visit | Scoliosis survey if scoliosis is clinically suspected; referral to orthopedist if indicated |
Psychiatric | Behavioral assessment | Screen for behavior problems at every visit; consultation w/psychiatrist &/or psychologist if behavioral atypia present | ADI™ & ADOS™, depending on age, for those w/suspected autism |
Miscellaneous / Other | Developmental monitoring by a developmental specialist | Annually, or at frequency directed by developmental specialist |
|
ADI = Autism Diagnostic Interview; ADOS = Autism Diagnostic Observation Schedule
Evaluation of Relatives at Risk
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.